These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 31666100)
1. Pharmacological and chemogenetic orexin/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson's disease. Stanojlovic M; Pallais JP; Lee MK; Kotz CM Mol Brain; 2019 Oct; 12(1):87. PubMed ID: 31666100 [TBL] [Abstract][Full Text] [Related]
2. Early Sociability and Social Memory Impairment in the A53T Mouse Model of Parkinson's Disease Are Ameliorated by Chemogenetic Modulation of Orexin Neuron Activity. Stanojlovic M; Pallais Yllescas JP; Vijayakumar A; Kotz C Mol Neurobiol; 2019 Dec; 56(12):8435-8450. PubMed ID: 31250383 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of Orexin/Hypocretin Neurons Ameliorates Elevated Physical Activity and Energy Expenditure in the A53T Mouse Model of Parkinson's Disease. Stanojlovic M; Pallais JP; Kotz CM Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33466831 [TBL] [Abstract][Full Text] [Related]
4. Chemogenetic Modulation of Orexin Neurons Reverses Changes in Anxiety and Locomotor Activity in the A53T Mouse Model of Parkinson's Disease. Stanojlovic M; Pallais JP; Kotz CM Front Neurosci; 2019; 13():702. PubMed ID: 31417337 [TBL] [Abstract][Full Text] [Related]
5. Chemogenetic activation of orexin/hypocretin neurons ameliorates aging-induced changes in behavior and energy expenditure. Stanojlovic M; Pallais Yllescas JP; Mavanji V; Kotz C Am J Physiol Regul Integr Comp Physiol; 2019 May; 316(5):R571-R583. PubMed ID: 30726119 [TBL] [Abstract][Full Text] [Related]
6. NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson's Disease. Sirabella R; Sisalli MJ; Costa G; Omura K; Ianniello G; Pinna A; Morelli M; Di Renzo GM; Annunziato L; Scorziello A Cell Death Dis; 2018 Jun; 9(7):725. PubMed ID: 29941946 [TBL] [Abstract][Full Text] [Related]
9. Depletion of hypothalamic hypocretin/orexin neurons correlates with impaired memory in a Parkinson's disease animal model. Oliveira LM; Henrique E; Bustelli IB; Netto NFC; Moreira TS; Takakura AC; Caetano AL Exp Neurol; 2020 Jan; 323():113110. PubMed ID: 31712126 [TBL] [Abstract][Full Text] [Related]
10. Orexin and Parkinson's disease: A protective neuropeptide with therapeutic potential. Liu C; Xue Y; Liu MF; Wang Y; Chen L Neurochem Int; 2020 Sep; 138():104754. PubMed ID: 32422324 [TBL] [Abstract][Full Text] [Related]
11. Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse. Savolainen MH; Albert K; Airavaara M; Myöhänen TT Exp Brain Res; 2017 Jul; 235(7):2189-2202. PubMed ID: 28439627 [TBL] [Abstract][Full Text] [Related]
12. Activation of orexin system facilitates anesthesia emergence and pain control. Zhou W; Cheung K; Kyu S; Wang L; Guan Z; Kurien PA; Bickler PE; Jan LY Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10740-E10747. PubMed ID: 30348769 [TBL] [Abstract][Full Text] [Related]
13. Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease. Paumier KL; Sukoff Rizzo SJ; Berger Z; Chen Y; Gonzales C; Kaftan E; Li L; Lotarski S; Monaghan M; Shen W; Stolyar P; Vasilyev D; Zaleska M; D Hirst W; Dunlop J PLoS One; 2013; 8(8):e70274. PubMed ID: 23936403 [TBL] [Abstract][Full Text] [Related]
14. Orexin pathway in Parkinson's disease: a review. Alrouji M; Al-Kuraishy HM; Al-Gareeb AI; Zaafar D; Batiha GE Mol Biol Rep; 2023 Jul; 50(7):6107-6120. PubMed ID: 37155018 [TBL] [Abstract][Full Text] [Related]
15. A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP. Kurz A; May C; Schmidt O; Müller T; Stephan C; Meyer HE; Gispert S; Auburger G; Marcus K J Neural Transm (Vienna); 2012 Mar; 119(3):297-312. PubMed ID: 21960009 [TBL] [Abstract][Full Text] [Related]
16. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Gomez-Isla T; Irizarry MC; Mariash A; Cheung B; Soto O; Schrump S; Sondel J; Kotilinek L; Day J; Schwarzschild MA; Cha JH; Newell K; Miller DW; Uéda K; Young AB; Hyman BT; Ashe KH Neurobiol Aging; 2003; 24(2):245-58. PubMed ID: 12498958 [TBL] [Abstract][Full Text] [Related]
17. Changes in hippocampal orexin 1 receptor expression involved in tooth pain-induced learning and memory impairment in rats. Raoof R; Esmaeili-Mahani S; Abbasnejad M; Raoof M; Sheibani V; Kooshki R; Amirkhosravi L; Rafie F Neuropeptides; 2015 Apr; 50():9-16. PubMed ID: 25817882 [TBL] [Abstract][Full Text] [Related]
18. Repetitive Closed-Head Impact Model of Engineered Rotational Acceleration Induces Long-Term Cognitive Impairments with Persistent Astrogliosis and Microgliosis in Mice. Chen H; Desai A; Kim HY J Neurotrauma; 2017 Jul; 34(14):2291-2302. PubMed ID: 28288551 [TBL] [Abstract][Full Text] [Related]
19. Cyclohexane produces behavioral deficits associated with astrogliosis and microglial reactivity in the adult hippocampus mouse brain. Campos-Ordonez T; Zarate-Lopez D; Galvez-Contreras AY; Moy-Lopez N; Guzman-Muniz J; Gonzalez-Perez O Cell Mol Neurobiol; 2015 May; 35(4):503-12. PubMed ID: 25433657 [TBL] [Abstract][Full Text] [Related]
20. A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia. Henrich MT; Geibl FF; Lee B; Chiu WH; Koprich JB; Brotchie JM; Timmermann L; Decher N; Matschke LA; Oertel WH Acta Neuropathol Commun; 2018 May; 6(1):39. PubMed ID: 29747690 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]